Publications
Detailed Information
Quality of life with first-line pembrolizumab for PD-L1epositive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Van Cutsem, E. | - |
dc.contributor.author | Valderrama, A. | - |
dc.contributor.author | Bang, Y. -J. | - |
dc.contributor.author | Fuchs, C. S. | - |
dc.contributor.author | Shitara, K. | - |
dc.contributor.author | Janjigian, Y. Y. | - |
dc.contributor.author | Qin, S. | - |
dc.contributor.author | Larson, T. G. | - |
dc.contributor.author | Shankaran, V. | - |
dc.contributor.author | Stein, S. | - |
dc.contributor.author | Norquist, J. M. | - |
dc.contributor.author | Kher, U. | - |
dc.contributor.author | Shah, S. | - |
dc.contributor.author | Alsina, M. | - |
dc.date.accessioned | 2023-03-20T08:52:16Z | - |
dc.date.available | 2023-03-20T08:52:16Z | - |
dc.date.created | 2021-10-18 | - |
dc.date.created | 2021-10-18 | - |
dc.date.created | 2021-10-18 | - |
dc.date.created | 2021-10-18 | - |
dc.date.created | 2021-10-18 | - |
dc.date.issued | 2021-08 | - |
dc.identifier.citation | Esmo Open, Vol.6 No.4, p. 100189 | - |
dc.identifier.issn | 2059-7029 | - |
dc.identifier.uri | https://hdl.handle.net/10371/189576 | - |
dc.description.abstract | Background: In the randomised phase III KEYNOTE-062 study, pembrolizumab was non-inferior to chemotherapy for overall survival in patients with programmed death-ligand 1 (PD-L1)-positive [combined positive score (CPS) 1] advanced gastric/gastroesophageal junction (GEJ) cancer. We present findings of prespecified health-related qualityof-life (HRQOL) analyses for pembrolizumab versus chemotherapy in this population. Materials and methods: HRQOL, a secondary endpoint, was measured in patients who received >= 1 dose of study treatment and completed >= 1 HRQOL questionnaire [European Organisation for the Research and Treatment of Cancer (EORTC) 30-question quality-of-life (QLQ-C30), EORTC 22-question quality-of-life gastric-cancer-specific module (QLQ-STO22)]. Least squares mean (LSM) change (baseline to week 18) in global health status/quality of life (GHS/QOL; EORTC QLQ-C30) and time to deterioration (TTD) in GHS/QOL, nausea/vomiting and appetite loss scores (EORTC QLQ-C30) and abdominal pain/discomfort scores (EORTC QLQ-STO22) were evaluated. Results: The HRQOL population comprised 495 patients with CPS >= 1 (pembrolizumab, 252; chemotherapy, 243). Compliance rates at week 18 were similar for pembrolizumab and chemotherapy (EORTC QLQ-C30, 87.9% and 81.9%; EORTC QLQ-STO22, 87.9% and 81.3%, respectively). There was no between-arm difference in LSM score change in GHS/QOL [-0.16; 95% confidence interval (CI) -5.01 to 4.69; P = 0.948]. The LSM score change for most subscales showed comparable worsening in both arms. TTD for GHS/QOL [hazard ratio (HR), 0.96; 95% CI, 0.67-1.38; P = 0.826], appetite loss (HR, 0.83; 95% CI, 0.58-1.20; P = 0.314) and pain (HR, 1.22; 95% CI, 0.78-1.91; P = 0.381) were similar between arms. Longer TTD was observed for pembrolizumab versus chemotherapy for nausea/vomiting (HR, 0.61; 95% CI, 0.44-0.85; P = 0.003). Conclusions: HRQOL was maintained with first-line treatment with pembrolizumab in patients with PD-L1epositive advanced gastric/GEJ cancer and was similar between pembrolizumab and chemotherapy in this population. | - |
dc.language | 영어 | - |
dc.publisher | BMJ PUBLISHING GROUP | - |
dc.title | Quality of life with first-line pembrolizumab for PD-L1epositive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.esmoop.2021.100189 | - |
dc.citation.journaltitle | Esmo Open | - |
dc.identifier.wosid | 000703610200012 | - |
dc.identifier.scopusid | 2-s2.0-85117623418 | - |
dc.citation.number | 4 | - |
dc.citation.startpage | 100189 | - |
dc.citation.volume | 6 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Bang, Y. -J. | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | gastroesophageal cancer | - |
dc.subject.keywordAuthor | pembrolizumab | - |
dc.subject.keywordAuthor | quality of life | - |
dc.subject.keywordAuthor | patient-reported outcomes | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.